Verapamil SR Tested as Beta Cell Protector in Adults With Type 1 Diabetes
A Phase 2 trial examines whether verapamil SR can slow beta cell loss and preserve insulin production in adults with Type 1 diabetes.
Summary
Type 1 diabetes results from the progressive destruction of insulin-producing beta cells by the immune system. Once lost, these cells are extremely difficult to restore, making preservation a top priority. This Phase 2 trial, conducted within the multinational INNODIA network, tested verapamil SR — a calcium channel blocker already approved for cardiovascular conditions — against placebo in adults with Type 1 diabetes. The rationale stems from preclinical and early clinical evidence suggesting verapamil can reduce beta cell stress and death by blocking thioredoxin-interacting protein (TXNIP), a molecule that rises in response to high glucose and drives beta cell apoptosis. Preserving residual beta cell function is highly relevant to healthspan, as even partial insulin production improves glucose control, reduces hypoglycemia risk, and lowers long-term complication rates. Full results are not yet publicly detailed in this abstract.
Detailed Summary
Type 1 diabetes is an autoimmune condition in which the body's own immune system destroys insulin-producing beta cells in the pancreas. Once this process begins, it is largely irreversible, and patients become dependent on external insulin for life. Slowing or halting this destruction — even partially — would represent a meaningful improvement in both quality of life and long-term healthspan, reducing the risk of cardiovascular, renal, and neurological complications that accumulate over decades of the disease.
This Phase 2 randomized controlled trial, embedded within the INNODIA network — a consortium of 31 academic institutions, six industry partners, and two patient organizations across Europe and the UK — evaluated verapamil SR (sustained-release) 120 mg versus placebo in adults with Type 1 diabetes. Verapamil is a well-established calcium channel blocker, but its interest in diabetes stems from a different mechanism: it suppresses TXNIP (thioredoxin-interacting protein), a stress-response molecule that triggers beta cell death in hyperglycemic conditions.
Preclinical studies and a landmark University of Alabama human trial previously suggested verapamil could preserve C-peptide levels — the gold-standard marker of residual beta cell function — in newly diagnosed Type 1 diabetes patients. The INNODIA trial extends this inquiry to a broader adult population within a rigorous, multinational infrastructure designed to standardize biomarker collection, staging, and outcome assessment.
The trial has been completed, though detailed efficacy and safety results are not disclosed in the available abstract. Key outcomes likely include C-peptide preservation, insulin requirements, and metabolic control markers.
Preserving even a fraction of native beta cell function has outsized clinical implications: patients with residual function experience fewer hypoglycemic episodes, better HbA1c trajectories, and reduced long-term complication burden — all directly relevant to healthspan extension in a chronic metabolic disease.
Key Findings
- Phase 2 trial tested verapamil SR 120 mg vs. placebo for beta cell preservation in adult Type 1 diabetes.
- Verapamil's proposed mechanism: suppressing TXNIP to reduce glucose-induced beta cell apoptosis.
- Trial embedded in INNODIA, a 31-institution multinational network standardizing T1D research.
- Preserving residual beta cell function reduces hypoglycemia risk and long-term complication rates.
- Trial is completed; full efficacy data not yet available in the public abstract.
Methodology
Phase 2 randomized controlled trial comparing verapamil SR 120 mg to placebo in adults with Type 1 diabetes, conducted under the INNODIA multinational network. The network's infrastructure standardizes biomarker collection, patient staging, and outcome evaluation across European and UK sites. Full protocol details, sample size, and primary endpoints are not disclosed in the available abstract.
Study Limitations
This summary is based on the abstract and ClinicalTrials.gov registration only, as the full study data are not publicly available; key efficacy outcomes, adverse events, and statistical results cannot be assessed. The abstract provides no information on sample size, duration, or primary endpoint definitions. Publication of full trial results is needed before clinical recommendations can be made.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: